Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Non-Current Debt (2023 - 2025)

Historic Non-Current Debt for OptimizeRx (OPRX) over the last 5 years, with Q3 2025 value amounting to $24.8 million.

  • OptimizeRx's Non-Current Debt fell 2547.33% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year decrease of 2547.33%. This contributed to the annual value of $30.8 million for FY2024, which is 997.63% down from last year.
  • Latest data reveals that OptimizeRx reported Non-Current Debt of $24.8 million as of Q3 2025, which was down 2547.33% from $25.1 million recorded in Q2 2025.
  • Over the past 5 years, OptimizeRx's Non-Current Debt peaked at $34.2 million during Q4 2023, and registered a low of $24.8 million during Q3 2025.
  • For the 3-year period, OptimizeRx's Non-Current Debt averaged around $30.3 million, with its median value being $31.6 million (2024).
  • Data for OptimizeRx's Non-Current Debt shows a peak YoY increase of 994.35% (in 2025) and a maximum YoY decrease of 2547.33% (in 2025) over the last 5 years.
  • Over the past 3 years, OptimizeRx's Non-Current Debt (Quarter) stood at $34.2 million in 2023, then decreased by 9.98% to $30.8 million in 2024, then fell by 19.52% to $24.8 million in 2025.
  • Its last three reported values are $24.8 million in Q3 2025, $25.1 million for Q2 2025, and $29.2 million during Q1 2025.